Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Healthtrust
Federal Trade Commission
Farmers Insurance
McKinsey
Medtronic
Baxter
Queensland Health
Teva
Covington

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,842,714

« Back to Dashboard

Which drugs does patent 7,842,714 protect, and when does it expire?

Patent 7,842,714 protects ACUVAIL and is included in one NDA.

This patent has forty-one patent family members in twenty countries.
Summary for Patent: 7,842,714
Title:Ketorolac tromethamine compositions for treating ocular pain
Abstract:The present invention provides an aqueous ophthalmic solution having an effective amount of ketorolac which includes carboxymethyl cellulose in an aqueous solution wherein the concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.
Inventor(s): Farnes; Eldon Q. (Laguna Beach, CA), Attar; Mayssa (Placentia, CA), Schiffman; Rhett M. (Laguna Beach, CA), Chang; Chin-Ming (Tustin, CA), Graham; Richard S. (Irvine, CA), Welty; Devin F. (Foothill Ranch, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:12/396,131
Patent Claim Types:
see list of patent claims
Formulation; Compound;

Drugs Protected by US Patent 7,842,714

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan ACUVAIL ketorolac tromethamine SOLUTION/DROPS;OPHTHALMIC 022427-001 Jul 22, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,842,714

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,192,571 Ketorolac tromethamine compositions for treating or preventing ocular pain ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,842,714

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 538775 ➤ Subscribe
Australia 2009202969 ➤ Subscribe
Australia 2009222016 ➤ Subscribe
Australia 2010289618 ➤ Subscribe
Australia 2011237646 ➤ Subscribe
Brazil PI0909100 ➤ Subscribe
Canada 2717520 ➤ Subscribe
Canada 2772622 ➤ Subscribe
Canada 2796071 ➤ Subscribe
China 102014869 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Accenture
US Army
Dow
AstraZeneca
Express Scripts
Federal Trade Commission
Farmers Insurance
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot